Company Description
Septerna is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by its proprietary Native Complex Platform.
Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Our lead product candidate, SEP-786, is a clinical-stage, oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism.
We have successfully completed Investigational New Drug (IND)-enabling studies and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of SEP-786.
We expect to report data from this trial in mid-2025.
| Country | United States |
| Founded | 2022 |
| IPO Date | Oct 25, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Jeffrey Finer, M.D., Ph.D. |
Contact Details
Address: 250 East Grand Avenue South San Francisco, CA 94080 United States | |
| Phone | (650) 338-3533 |
| Website | septerna.com |
Stock Details
| Ticker Symbol | SEPN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001984086 |
| Employer ID | 84-3891440 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey Finer, M.D., Ph.D. | Chief Executive Officer, President and Director |
| Liz Bhatt, M.S., M.B.A. | Chief Operating Officer |
| Jae B. Kim, M.D. | Chief Medical Officer |
| Samira Shaikhly | Chief People Officer |
| Uwe Klein, Ph.D. | Senior Vice President, Biological Sciences |
| Daniel Long, D.Phil. | Senior Vice President, Drug Discovery |
| Jeffrey Tong, Ph.D. | Chairman and Director |
| Abraham Bassan, M.S. | Director |
| Alan Ezekowitz, M.D., D.Phil. | Director |
| Bernard Coulie, M.D., Ph.D., M.B.A. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 25, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 25, 2024 | 424B4 | Prospectus |
| Oct 24, 2024 | EFFECT | Notice of Effectiveness |
| Oct 24, 2024 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Oct 24, 2024 | CERT | Certification by an exchange approving securities for listing |
| Oct 24, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 22, 2024 | 8-A12B | Registration of securities |
| Oct 21, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 2, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 12, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |